Celldex Therapeutics, Inc.
CLDX
$18.30
$0.502.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.74% | -10.09% | -17.51% | -11.74% | -63.50% |
| Total Depreciation and Amortization | 7.91% | 2.48% | 5.42% | 6.75% | 12.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.58% | -3.69% | -28.52% | 26.36% | 26.24% |
| Change in Net Operating Assets | 48.08% | -248.34% | 286.99% | -314.25% | 7,563.08% |
| Cash from Operations | 0.18% | -191.35% | -7.84% | -42.25% | -49.49% |
| Capital Expenditure | -13.51% | -247.13% | 33.17% | 41.20% | -183.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.55% | 309.24% | -3,051.02% | -692.37% | -642.15% |
| Cash from Investing | 114.05% | 310.08% | -4,114.00% | -699.61% | -648.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.82% | 382.10% | 2,690.98% | 62,740.35% | 15,482.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.82% | 382.10% | 2,690.98% | 62,740.35% | 15,482.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.79% | 10.58% | -179.31% | 225.03% | 26.13% |